Profile data is unavailable for this security.
About the company
Zymeworks Inc. is a global biotechnology company. The Company is engaged in the discovery, development, and commercialization of multifunctional biotherapeutics to treat cancer and other serious diseases. Its complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop differentiated antibody-based therapeutic candidates. Its platforms include Azymetric, Drug Conjugate Platforms, EFECT, and ProTECT. Its lead product candidate, zanidatamab, is a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its second product candidate, zanidatamab zovodotin, combines the biparatopic antibody design of zanidatamab with its ZymeLink auristatin antibody-drug conjugate (ADC) technology, comprised of its cytotoxin (cancer cell-killing compound) and cleavable linker. Its pipeline includes four preclinical candidates: ZW191, ZW171, ZW220, and ZW251.
- Revenue in USD (TTM)62.20m
- Net income in USD-113.67m
- Incorporated2022
- Employees294.00
- LocationZymeworks Inc108 Patriot Drive, Suite AMIDDLETOWN 19709United StatesUSA
- Phone+1 (302) 274-8744
- Fax+1 (302) 655-5049
- Websitehttps://www.zymeworks.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| AbCellera Biologics Inc | 32.96m | -175.80m | 803.40m | 586.00 | -- | 0.7337 | -- | 24.37 | -0.5999 | -0.5999 | 0.1125 | 3.71 | 0.0227 | -- | 0.958 | 56,250.85 | -12.10 | 6.08 | -12.95 | 6.67 | -- | -- | -533.32 | 24.69 | -- | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Capricor Therapeutics Inc | 23.23m | -34.11m | 808.91m | 101.00 | -- | 10.51 | -- | 34.82 | -1.06 | -1.06 | 0.7316 | 1.69 | 0.3571 | -- | 48.53 | 229,980.70 | -52.44 | -54.12 | -88.95 | -75.13 | -- | -- | -146.86 | -316.25 | -- | -- | 0.0471 | -- | 886.81 | 72.02 | 23.20 | -- | 45.27 | -- |
| Rapport Therapeutics Inc | -100.00bn | -100.00bn | 823.70m | 58.00 | -- | 2.55 | -- | -- | -- | -- | -- | 8.83 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -226.57 | -- | -- | -- |
| Bicara Therapeutics Inc | -100.00bn | -100.00bn | 870.14m | 32.00 | -- | 1.90 | -- | -- | -- | -- | -- | 9.37 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -37.36 | -- | -- | -- |
| Arrivent Biopharma Inc | 0.00 | -81.05m | 893.05m | 40.00 | -- | 3.23 | -- | -- | -2.62 | -2.62 | 0.00 | 8.24 | 0.00 | -- | -- | 0.00 | -34.15 | -- | -36.07 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -87.86 | -- | -- | -- |
| Nuvation Bio Inc | 2.16m | -532.28m | 908.73m | 203.00 | -- | 1.81 | -- | 420.32 | -2.17 | -2.17 | 0.009 | 1.50 | 0.0036 | -- | 0.5936 | 42,392.16 | -88.53 | -16.27 | -94.44 | -16.65 | -32.38 | -- | -24,619.84 | -- | -- | -- | 0.0165 | -- | -- | -- | 27.25 | -- | -- | -- |
| Septerna Inc | 840.00 | -10.27k | 915.24m | 68.00 | -- | -- | -- | 1,089,573.00 | -0.0003 | -0.0003 | 0.00002 | 0.0037 | -- | -- | -- | 12.35 | -- | -- | -- | -- | -- | -- | -792.86 | -- | -- | -- | 0.00 | -- | -- | -- | 102.06 | -- | -- | -- |
| Lenz Therapeutics Inc | 0.00 | -60.04m | 943.83m | 6.00 | -- | 4.38 | -- | -- | -7.08 | -7.08 | 0.00 | 7.83 | 0.00 | -- | -- | 0.00 | -24.49 | -- | -25.55 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.35 | -- | -- | -- |
| Zymeworks Inc | 62.20m | -113.67m | 946.15m | 294.00 | -- | 2.62 | -- | 15.21 | -1.51 | -1.51 | 0.8306 | 5.23 | 0.1192 | -- | 1.37 | 228,672.80 | -21.79 | -22.58 | -25.64 | -26.90 | -- | -- | -182.75 | -91.17 | -- | -- | 0.00009 | -- | -81.57 | 7.47 | -195.44 | -- | 3.58 | -- |
| Upstream Bio Inc | -100.00bn | -100.00bn | 954.02m | 38.00 | -- | -- | -- | -- | -- | -- | -- | 4.30 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | 96.37 | -- | -60.28 | -- | -- | -- |
| Vir Biotechnology Inc | 78.62m | -533.34m | 957.15m | 587.00 | -- | 0.7658 | -- | 12.17 | -3.92 | -3.92 | 0.5794 | 9.08 | 0.0444 | -- | -- | 133,931.90 | -30.10 | -0.6081 | -32.71 | -0.7192 | 98.78 | -- | -678.40 | -1.53 | -- | -- | 0.00 | -- | -94.67 | 51.87 | -219.24 | -- | 16.77 | -- |
| Cogent Biosciences Inc | 0.00 | -242.30m | 982.87m | 164.00 | -- | 4.86 | -- | -- | -2.48 | -2.48 | 0.00 | 2.85 | 0.00 | -- | -- | 0.00 | -65.53 | -49.53 | -74.36 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| 89bio Inc | 0.00 | -288.96m | 985.34m | 70.00 | -- | 2.35 | -- | -- | -2.91 | -2.91 | 0.00 | 3.56 | 0.00 | -- | -- | 0.00 | -62.93 | -45.50 | -67.67 | -49.31 | -- | -- | -- | -- | -- | -- | 0.0859 | -- | -- | -- | -39.37 | -- | -36.58 | -- |
| Applied Therapeutics Inc | -211.00k | -187.31m | 1.08bn | 37.00 | -- | 183.07 | -- | -- | -1.53 | -1.53 | -0.0017 | 0.0506 | -0.0028 | -- | -- | -8,440.00 | -246.85 | -140.37 | -- | -240.93 | -- | -- | -- | -4,476.42 | -- | -- | 0.00 | -- | -- | -- | -45.15 | -- | -- | -- |
| Gyre Therapeutics Inc | 191.34m | -76.96m | 1.10bn | 593.00 | -- | 15.95 | -- | 5.74 | -0.2281 | -0.2281 | 1.35 | 0.7366 | 2.83 | -- | 19.64 | 322,656.00 | -95.21 | -73.59 | -154.33 | -99.94 | 96.16 | -- | -33.64 | -205.62 | 3.29 | -- | 0.00 | -- | 14,188.41 | 616.69 | -1,027.55 | -- | 86.95 | -- |
Data as of Nov 22 2024. Currency figures normalised to Zymeworks Inc's reporting currency: US Dollar USD
52.69%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 15 Oct 2024 | 13.44m | 15.65% |
| BVF Partners LPas of 15 Oct 2024 | 5.87m | 6.84% |
| Redmile Group LLCas of 30 Sep 2024 | 5.10m | 5.94% |
| Morgan Stanley & Co. LLCas of 30 Sep 2024 | 5.09m | 5.93% |
| Rubric Capital Management LPas of 30 Sep 2024 | 3.92m | 4.56% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.58m | 4.17% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.78m | 3.24% |
| Perceptive Advisors LLCas of 30 Sep 2024 | 2.18m | 2.54% |
| BNP Paribas Asset Management USA, Inc.as of 30 Sep 2024 | 1.78m | 2.07% |
| HBM Partners AG (Investment Management)as of 31 Mar 2024 | 1.52m | 1.77% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
